scholarly journals Current Practice of Anti-TNF-α Treatment in Inflammatory Bowel Disease: Results From A National Survey in Sweden

2014 ◽  
Vol 3 (12) ◽  
pp. 1396-1400
Author(s):  
Ulf Hindorf ◽  
◽  
Sven Almer
Keyword(s):  
Inflammatory Bowel Disease ◽  
National Survey ◽  
Bowel Disease ◽  
Current Practice ◽  
Tnf Α ◽  
Inflammatory Bowel

scholarly journals Cutaneous Manifestations in Biological-Treated Inflammatory Bowel Disease Patients: A Narrative Review

2021 ◽  
Vol 10 (5) ◽  
pp. 1040
Author(s):  
Jo L. W. Lambert ◽  
Sofie De Schepper ◽  
Reinhart Speeckaert
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Cutaneous Manifestations ◽  
Cutaneous Infections ◽  
Tnf Α ◽  
Common Skin ◽  
Receptor Blockers ◽  
Infusion Reactions ◽  
Inflammatory Bowel ◽  
Lichenoid Reactions

The biologic era has greatly improved the treatment of Crohn’s disease and ulcerative colitis. Biologics can however induce a wide variety of skin eruptions, especially those targeting the TNF-α and Th17 pathway. These include infusion reactions, eczema, psoriasis, lupus, alopecia areata, vitiligo, lichenoid reactions, granulomatous disorders, vasculitis, skin cancer, and cutaneous infections. It is important to recognize these conditions as treatment-induced adverse reactions and adapt the treatment strategy accordingly. Some conditions can be treated topically while others require cessation or switch of the biological therapy. TNF-α antagonists have the highest rate adverse skin eruptions followed by ustekinumab and anti-integrin receptor blockers. In this review, we provide an overview of the most common skin eruptions which can be encountered in clinical practice when treating IBD (Inflammatory bowel disease) patients and propose a therapeutic approach for each condition.

Sa1046 Improving Medical Record Documentation of Clinical Encounters in Inflammatory Bowel Disease (IBD) Patients: A Review of Current Practice

2015 ◽  
Vol 148 (4) ◽  
pp. S-206
Author(s):  
Ashraf A. Almashhrawi ◽  
Fazia A. Mir ◽  
Amin Mahdi ◽  
Anjana Sathyamurthy ◽  
Richard Madsen ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Medical Record ◽  
Bowel Disease ◽  
Current Practice ◽  
Clinical Encounters ◽  
Inflammatory Bowel ◽  
Medical Record Documentation

scholarly journals Inflammatory bowel disease: the role of inflammatory cytokine gene polymorphisms

2004 ◽  
Vol 13 (3) ◽  
pp. 181-187 ◽  
Author(s):  
Joanna Balding ◽  
Wendy J. Livingstone ◽  
Judith Conroy ◽  
Lesley Mynett-Johnson ◽  
Donald G. Weir ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Disease Incidence ◽  
Strong Association ◽  
Tnf Α ◽  
Genes Encoding ◽  
Inflammatory Processes ◽  
Inflammatory Bowel ◽  
Cytokine Gene Polymorphisms

THE mechanisms responsible for development of inflammatory bowel disease (IBD) have not been fully elucidated, although the main cause of disease pathology is attributed to up-regulated inflammatory processes. The aim of this study was to investigate frequencies of polymorphisms in genes encoding pro-inflammatory and anti-inflammatory markers in IBD patients and controls. We determined genotypes of patients with IBD (n=172) and healthy controls (n=389) for polymorphisms in genes encoding various cytokines (interleukin (IL)-1β, IL-6, tumour necrosis factor (TNF), IL-10, IL-1 receptor antagonist). Association of these genotypes to disease incidence and pathophysiology was investigated. No strong association was found with occurrence of IBD. Variation was observed between the ulcerative colitis study group and the control population for the TNF-α-308 polymorphism (p=0.0135). There was also variation in the frequency of IL-6-174 and TNF-α-308 genotypes in the ulcerative colitis group compared with the Crohn's disease group (p=0.01). We concluded that polymorphisms in inflammatory genes are associated with variations in IBD phenotype and disease susceptibility. Whether the polymorphisms are directly involved in regulating cytokine production, and consequently pathophysiology of IBD, or serve merely as markers in linkage disequilibrium with susceptibility genes remains unclear.

scholarly journals Synthesis and evaluation of 6-heteroarylamino-2,4,5-trimethylpyridin-3-ols as inhibitors of TNF-α-induced cell adhesion and inflammatory bowel disease

MedChemComm ◽  
2018 ◽  
Vol 9 (8) ◽  
pp. 1305-1310 ◽  
Author(s):  
Sang Won Park ◽  
Suhrid Banskota ◽  
Pallavi Gurung ◽  
You Jin Jin ◽  
Han-eol Kang ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Cell Adhesion ◽  
Bowel Disease ◽  
Tnf Α ◽  
Inflammatory Bowel ◽  
Anti Inflammatory

Novel series of anti-inflammatory bowel disease (IBD) agent was identified through TNF-α-induced cell adhesion.

Sa1023 AN INDIAN NATIONAL SURVEY OF THERAPEUTIC DRUG MONITORING WITH ANTI-TNF MEDICATIONS IN INFLAMMATORY BOWEL DISEASE

2020 ◽  
Vol 158 (6) ◽  
pp. S-246
Author(s):  
Gaurav B. Nigam ◽  
Rajan N. Patel ◽  
Raj G. Jatale ◽  
Govind K. Makharia ◽  
Vineet Ahuja ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Therapeutic Drug Monitoring ◽  
National Survey ◽  
Bowel Disease ◽  
Drug Monitoring ◽  
Therapeutic Drug ◽  
Inflammatory Bowel

scholarly journals Mo1900 – TNF-α Inhibitors and Risk of Type 2 Diabetes in Patients with Inflammatory Bowel Disease

2019 ◽  
Vol 156 (6) ◽  
pp. S-879
Author(s):  
Marie Villumsen ◽  
Nynne Nyboe Andersen ◽  
Tine Jess ◽  
Kristine Allin
Keyword(s):  
Type 2 Diabetes ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Tnf Α ◽  
Inflammatory Bowel

Characterization of γδ T Cells in Intestinal Mucosa From Patients With Early-Onset or Long-Standing Inflammatory Bowel Disease and Their Correlation With Clinical Status

2019 ◽  
Vol 13 (7) ◽  
pp. 873-883 ◽  
Author(s):  
Elena Lo Presti ◽  
Roberto Di Mitri ◽  
Filippo Mocciaro ◽  
Anna Barbara Di Stefano ◽  
Nunzia Scibetta ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
T Cells ◽  
Intestinal Mucosa ◽  
Bowel Disease ◽  
Early Onset ◽  
Γδ T Cells ◽  
Healthy Tissue ◽  
Effector Memory ◽  
Tnf Α ◽  
Inflammatory Bowel

Abstract Background and Aims Inflammatory bowel disease [IBD] is a complex chronic inflammatory disease of the human gut with no clear aetiology. Traditionally, dysregulated adaptive immune responses play an important role even though accumulating evidence suggests a role also for innate immunity. Because of the well-known plasticity of γδ T cells, we investigated their percentage occurrence, phenotypic features and effector functions in the intestinal mucosa of early-onset and long-standing IBD patients, as compared to healthy subjects. Methods Fresh biopsies from 30 Crohn’s disease and ulcerative colitis patients were obtained and digested, and cells were analysed by flow cytometry. Results We found a reduced frequency of Vδ1 T cells in tissue from early and late IBD patients (2.24% and 1.95%, respectively, vs 5.44% in healthy tissue) but an increased frequency of Vδ2 T cells in the gut of late IBD patients (3.19% in late patients vs 1.5% in early patients and 1.65% in healthy tissue). The infiltrating Vδ2 T cells had predominant effector memory and terminally differentiated phenotypes and produced elevated levels of tumour necrosis factor-α [TNF-α] and interleukin-17 [IL-17]. The frequency of tissue Vδ2 T cells correlated with the extent of the inflammatory response and the severity of IBD. Conclusion Our study shows that tissue Vδ1 T cells are decreased in IBD patients while Vδ2 T cells are increased in the gut of IBD patients and contribute to TNF-α production. Moreover, we identify an as yet unappreciated role of Vδ2 T cells in IL-17 production in the gut of long-standing IBD patients, suggesting that they also participate in the chronic inflammatory process.

Sign in / Sign up

Export Citation Format

Share Document